Japanese partner discourages Tavneos after deathsdiscourages Tavneos after deaths
Kissei Pharmaceutical in Japan is advising doctors to stop prescribing Amgen’s Tavneos after reports of deaths among patients who took the rare-disease drug.
The move adds pressure on the medicine, which has already drawn scrutiny from health regulators in multiple countries and could affect its future use more widely.
Japanese Perspective
Kissei Pharmaceutical is warning doctors not to start new patients on Tavneos and is urging caution after the deaths were reported. Its position reflects concern that the drug’s safety profile needs closer review before wider use continues.
Company and Regulatory Perspective
Amgen’s drug remains under scrutiny as health authorities and partners weigh whether the reported deaths point to a broader safety issue. The case shows how post-market monitoring can quickly change the outlook for medicines used in rare diseases.
- Japan has one of the world’s largest aging populations, which can make drug safety monitoring especially important.
- Rare-disease medicines often face small patient pools, so even limited safety signals can trigger major reviews.
- Post-market drug warnings can emerge years after approval, when a medicine is used in broader real-world settings.
